Form D · Pharmaceuticals
Belhaven Biopharma Inc.
Chapel Hill, NC · CIK 0001873965
Offering snapshot reported Oct 15, 2025 · SEC filing
- Reported sold
- $32.3M Offering amount: $32.3M
- Investors reported
- 222 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 4, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 15, 2025 | Initial | $32,289,627 | No comparison | 222 | SEC filing |
Offering details
- Securities
- Equity, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-560900
Source: Form D, filed Oct 15, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Scott David Lyman | Director, Executive |
| David Algon Neal | Director, Executive |
| Wes Wheeler | Director |
| Derek Winstanly | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
84406 Winslow
Chapel Hill, NC, 27517
Phone: 919-656-8658
Chapel Hill, NC, 27517
Phone: 919-656-8658